Targeting death-inducing receptors in cancer therapy

Oncogene

Volumn 26, Issue 25, 2007, Pages 3745-3757

  Takeda, K ^a,b   Stagg, J ^b   Yagita, H ^a   Okumura, K ^a   Smyth, M J ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Anti tumor immune response; Apoptosis; DR4; DR5; TNF superfamily; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CD137 LIGAND MONOCLONAL ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CETUXIMAB; CYTOKINE ANTIBODY; DEATH RECEPTOR 4; DEATH RECEPTOR 4 MONOCLONAL ANTIBODY; DEATH RECEPTOR 5; DEATH RECEPTOR 5 MONOCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 MONOCLONAL ANTIBODY; INTERFERON; MD5 1; PROTEASOME INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LEUKEMIA; CANCER; CANCER CHEMOTHERAPY; CELL DEATH; CELLULAR IMMUNITY; CROSS LINKING; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; GENE MUTATION; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOLECULAR INTERACTION; MYELOABLATIVE CONDITIONING; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT DURATION; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, NEOPLASM; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 34249663310     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210374     Document Type: Review

References (131)

1. Akiyama K, Ebihara S, Yada A, Matsumura K, Aiba S, Nukiwa T et al. (2003). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. J Immunol 170: 1641-1648.
2. Albert ML, Sauter B, Bhardwaj N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86-89.
3. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. (2003). Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) α, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 9: 4537-4545.
4. Ashkenazi A. (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-430.
5. Ashkenazi A, Dixit VM. (1998). Death receptors: signaling and modulation. Science 281: 1305-1308.
6. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162.
7. Basombrio MA. (1970). Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res 30: 2458-2462.
8. Bianco R, Daniele G, Ciardiello F, Tortora G. (2005). Monoclonal antibodies targeting the epidermal growth factor receptor. Curr Drug Targets 6: 275-287.
9. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S et al. (2003). Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9: 3731-3741.
10. Bucur O, Ray S, Bucur MC, Almasan A. (2006). APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 11: 1549-1568.
11. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289.
12. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. (2002). Apoptosis and interferons: role of interferonstimulated genes as mediators of apoptosis. J Immunol 169: 847-855.
13. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH et al. (2003). IFN-β pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligandinduced apoptosis. Apoptosis 8: 237-249.
14. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL et al. (2000). Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97: 1754-1759.
15. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H et al. (2001). Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166: 4891-4898.
16. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G et al. (2005). Preligand assembly domainmediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 102: 18099-18104.
17. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. (2004). Tumor suppressor IRF-1 mediated retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 23: 3051-3060.
18. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. (1998). Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95: 652-656.
19. Clynes RA, Towers TL, Presta LG, Ravetch JV. (2000). Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446.
20. Cragg MS, French RR, Glennie MJ. (1999). Signaling antibodies in cancer therapy. Curr Opin Immunol 11: 541-547.
21. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. (1988). A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 62: 2467-2471.
22. Creaven PJ, Plager JE, Dupere S, Huben RP, Takita H, Mittelman A et al. (1987). Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20: 137-144.
23. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. (2002). Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356-1361.
24. Croft M. (2003a). Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3: 609-620.
25. Croft M. (2003b). Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 14: 265-273.
26. Danial NN, Korsmeyer SJ. (2004). Cell death: critical control points. Cell 116: 205-219.
27. Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch'En P et al. (2005). Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 15: 430-438.
28. de Bono JS, Rowinsky EK. (2002). Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br Med Bull 64: 227-254.
29. Degli-Esposti M. (1999). To die or not to die -the quest of the TRAIL receptors. J Leukoc Biol 65: 535-542.
30. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. (2002). Antitumor monoclonal antibodies enhance crosspresentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195: 125-133.
31. Diehl GE, Yue HH, Hsieh K, Kuang AA, Ho M, Morici LA et al. (2004). TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21: 877-889.
32. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ et al. (1999). CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5: 774-779.
33. Dunn GP, Old LJ, Schreiber RD. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
34. Egen JG, Kuhns MS, Allison JP. (2002). CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3: 611-618.
35. French RR, Chan HT, Tutt AL, Glennie MJ. (1999). CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5: 548-553.
36. Fulda S, Debatin KM. (2002). IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the stat1 pathway. Oncogene 21: 2295-2308.
37. Fulda S, Wick W, Weller M, Debatin KM. (2002). Smac agonists sensitize for Apo2L/TRAIL- or anticancer druginduced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815.
38. Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H et al. (2002). Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 14: 275-286.
39. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W et al. (1995). Involvement of the CD95 (APO-1/ Fas) receptor and ligand in liver damage. J Exp Med 182: 1223-1230.
40. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K et al. (2005). Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42: 588-597.
41. Gelderman KA, Tomlinson S, Ross GD, Gorter A. (2004). Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25: 158-164.
42. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M et al. (2005). Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130: 501-510.
43. Gliniak B, Le T. (1999). Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59: 6153-6158.
44. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH et al. (1999). Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 162: 2597-2605.
45. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
46. Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC et al. (2004). TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64: 8502-8506.
47. Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ et al. (2004). NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 172: 123-129.
48. Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT et al. (1991). Phase II studies of recombinant human tumor necrosis factor α in patients with malignant disease: a summary of the southwest oncology group experience. J Immunother 10: 426-431.
49. Higuchi H, Bronk SF, Taniai M, Canbay A, Gores GJ. (2002). Cholestasis increases tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. J Pharmacol Exp Ther 303: 461-467.
50. Hinoda Y, Sasaki S, Ishida T, Imai K. (2004). Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 95: 621-625.
51. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al. (2001). Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960.
52. Itoh N, Nagata S. (1993). A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 268: 10932-10937.
53. Janssen HL, Higuchi H, Abdulkarim A, Gores GJ. (2003). Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 39: 414-420.
54. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR et al. (2000). Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564-567.
55. Johnstone RW, Ruefli AA, Lowe SW. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164.
56. Kaufmann SH, Steensma DP. (2005). On the TRAIL of a new therapy for leukemia. Leukemia 19: 2195-2202.
57. Kelley SK, Ashkenazi A. (2004). Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4: 333-339.
58. Khong HT, Restifo NP. (2002). Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 3: 999-1005.
59. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. (2000). Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6: 335-346.
60. Kircheis R, Wightman L, Kursa M, Ostermann E, Wagner E. (2002). Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. Gene Therapy 9: 731-735.
61. Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J. (2005). Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosisinducing ligand (TRAIL). J Invest Dermatol 125: 1010-1019.
62. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. (2001). Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383-385.
63. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P et al. (2002). Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog bax. Nat Med 8: 274-281.
64. LeBlanc HN, Ashkenazi A. (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75.
65. Lee SJ, Myers L, Muralimohan G, Dai J, Qiao Y, Li Z et al. (2004). 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol 173: 3002-3012.
66. Leverkus M, Walczak H, McLellan A, Fries HW, Terbeck G, Brocker EB et al. (2000). Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood 96: 2628-2631.
67. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. (2004). A small molecule Smac mimic potentiates TRAIL- and TNFa-mediated cell death. Science 305: 1471-1474.
68. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R et al. (2006). Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25: 5145-5154.
69. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. (1998). NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 190: 167-172.
70. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE et al. (1997). Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3: 682-685.
71. Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ et al. (2004). Interferon γ enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 64: 8349-8356.
72. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al. (2001). TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795-804.
73. Mori E, Thomas M, Motoki K, Nakazawa K, Tahara T, Tomizuka K et al. (2004). Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 11: 203-207.
74. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R et al. (2005). Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Clin Cancer Res 11: 3126-3135.
75. Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C et al. (2003). Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 17: 94-96.
76. Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, Manns MP et al. (2005). Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 54: 1590-1596.
77. Nicholson DW. (2000). From bench to clinic with apoptosisbased therapeutic agents. Nature 407: 810-816.
78. O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW, Williamson KE. (2006). Targeting death receptors in bladder, prostate and renal cancer. J Urol 175: 432-438.
79. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809.
80. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. (2003). Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22: 2034-2044.
81. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP et al. (2004). Role of tumor necrosis factor-related apoptosis-inducing ligand in interferoninduced apoptosis in human bladder cancer cells. Cancer Res 64: 8973-8979.
82. Pardoll D, Allison J. (2004). Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10: 887-892.
83. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D et al. (1998). Phase II study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671.
84. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690.
85. Pollard JW. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
86. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT et al. (1993). Inducible T cell antigen 4-1B. Analysis of expression and function. J Immunol 150: 771-781.
87. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C et al. (2005). HGS-ETR1, a fully human TRAILreceptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92: 1430-1441.
88. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. (2001). Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22: 41-47.
89. Qin J, Chaturvedi V, Bonish B, Nickoloff BJ. (2001). Avoiding premature apoptosis of normal epidermal cells. Nat Med 7: 385-386.
90. Rafiq K, Bergtold A, Clynes R. (2002). Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110: 71-79.
91. Reed JC, Kitada S, Kim Y, Byrd J. (2002). Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol 29: 10-24.
92. Rowinsky EK. (2005). Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23: 9394-9407.
93. Salomon DS, Brandt R, Ciardiello F, Normanno N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232.
94. Sayers TJ, Murphy WJ. (2006). Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 55: 76-84.
95. Schmitz I, Kirchhoff S, Krammer PH. (2000). Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 32: 1123-1136.
96. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D et al. (2003). Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL). J Biol Chem 278: 5444-5454.
97. + cytotoxic T cells. Leukemia 15: 1619-1626.
98. Shankar S, Srivastava RK. (2004). Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7: 139-156.
99. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS et al. (1998). p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α. Cancer Res 58: 1593-1598.
100. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821.
101. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186: 47-55.
102. Smith MR. (2003). Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359-7368.
103. Smyth MJ, Hayakawa Y, Cretney E, Zerafa N, Sivakumar P, Yagita H et al. (2006). IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy. J Immunol 176: 6347-6355.
104. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. (2003). Nature's TRAIL -on a path to cancer immunotherapy. Immunity 18: 1-6.
105. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z et al. (1999). Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5: 780-787.
106. Steller H. (1995). Mechanisms and genes of cellular suicide. Science 267: 1445-1449.
107. Takahashi C, Mittler RS, Vella AT. (1999). 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 162: 5037-5040.
108. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H et al. (2002). Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195: 161-169.
109. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE et al. (2004). Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199: 437-448.
110. Takimoto R, El-Deiry WS. (2000). Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19: 1735-1743.
111. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. (1993). A novel domain within the 55 kd TNF receptor signals cell death. Cell 74: 845-853.
112. Thompson CB. (1995). Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462.
113. Timmer T, de Vries EG, de Jong S. (2002). Fas receptormediated apoptosis: a clinical application? J Pathol 196: 125-134.
114. Trcka J, Moroi Y, Clynes RA, Goldberg SM, Bergtold A, Perales MA et al. (2002). Redundant and alternative roles for activating fc receptors and complement in an antibodydependent model of autoimmune vitiligo. Immunity 16: 861-868.
115. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC et al. (2000). Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275: 23319-23325.
116. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS et al. (2006). Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12: 693-698.
117. van Geelen CM, de Vries EG, Le TK, van Weeghel RP, de Jong S. (2003). Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer 89: 363-373.
118. Varela N, Munoz-Pinedo C, Ruiz-Ruiz C, Robledo G, Pedroso M, Lopez-Rivas A. (2001). Interferon-γ sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism. J Biol Chem 276: 17779-17787.
119. Vassalli P. (1992). The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411-452.
120. Voelkel-Johnson C. (2003). An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol Ther 2: 283-290.
121. Wajant H, Pfizenmaier K, Scheurich P. (2002). TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7: 449-459.
122. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163.
123. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. (1999). Tumor necrosis factor receptor and fas signaling mechanisms. Annu Rev Immunol 17: 331-367.
124. Watts TH. (2005). TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23-68.
125. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI et al. (2002). Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 109: 651-659.
126. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
127. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. (2004). TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783.
128. Zeng Y, Wu XX, Fiscella M, Shimada O, Humphreys R, Albert V et al. (2006). Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 28: 421-430.
129. Zhang M, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Brechbiel MW et al. (2004). Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res 64: 5825-5829.
130. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. (1999). Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753.
131. zum Buschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H. (2002). Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 62: 2244-2247.